<code id='DDAD4F1D36'></code><style id='DDAD4F1D36'></style>
    • <acronym id='DDAD4F1D36'></acronym>
      <center id='DDAD4F1D36'><center id='DDAD4F1D36'><tfoot id='DDAD4F1D36'></tfoot></center><abbr id='DDAD4F1D36'><dir id='DDAD4F1D36'><tfoot id='DDAD4F1D36'></tfoot><noframes id='DDAD4F1D36'>

    • <optgroup id='DDAD4F1D36'><strike id='DDAD4F1D36'><sup id='DDAD4F1D36'></sup></strike><code id='DDAD4F1D36'></code></optgroup>
        1. <b id='DDAD4F1D36'><label id='DDAD4F1D36'><select id='DDAD4F1D36'><dt id='DDAD4F1D36'><span id='DDAD4F1D36'></span></dt></select></label></b><u id='DDAD4F1D36'></u>
          <i id='DDAD4F1D36'><strike id='DDAD4F1D36'><tt id='DDAD4F1D36'><pre id='DDAD4F1D36'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:leisure time    Page View:88489

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In